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Abstract (max 250 words) 
Human pluripotent stem cells represent a unique source for cell-based therapies and regenerative 
medicine. The intrinsic features of these cells such as their easy accessibility and their capacity to be 
expanded indefinitely overcome some limitations of conventional adult stem cells. Furthermore, the 
possibility to derive patient-specific induced pluripotent stem (iPS) cells in combination with the 
current development of gene modification methods could be used for autologous cell therapies of some 
genetic diseases. In particular, muscular dystrophies are considered to be a good candidate due to the 
lack of efficacious therapeutic treatments for patients to date, and in view of the encouraging results 
arising from recent preclinical studies. Some hurdles, including possible genetic instability and their 
efficient differentiation into muscle progenitors through vector-/transgene-free methods have still to be 
overcome or need further optimization. Additionally, engraftment and functional contribution to 
muscle regeneration in pre-clinical models needs to be carefully assessed before clinical translation. 
This review offers a summary of the advanced methods recently developed to derive muscle 
progenitors from pluripotent stem cells, as well as gene therapy by gene addition and gene editing 
methods using ZFNs, TALENs or CRISPR/Cas9. We also discuss the main issues that need to be 
addressed for successful clinical translation of genetically corrected patient-specific pluripotent stem 
cells in autologous transplantation trials for skeletal muscle disorders. 
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Introduction 
Skeletal muscle is a dynamic tissue capable of responding to exercise, injury or disease with a 
remarkable regenerative response. The ability of this tissue in providing a complete regeneration is 
primarily due to a pool of resident stem cells named satellite cells [1]. In addition to these cells, other 
stem/progenitor cells have been shown to participate in muscle regeneration. Subsequently, there has 
been much interest in the use of adult stem cells capable of myogenesis as a cellular therapy for 
degenerative muscle disorders  (reviewed in [2] and in this issue by Sampaolesi et al.). However, the 
regenerative potential of these adult stem cells is not unlimited and exhaustion/dysfunction of muscle 
stem/progenitor cells has been reported in several muscular dystrophies and/or after expansion in vitro 
[3–9]. Recent studies have suggested the possibility of using embryonic stem (ES) cells [10,11] or 
induced pluripotent stem (iPS) cells [12,13] as a source for generating myogenic cells to use in cellular 
therapies for muscle regeneration. ES cells and iPS cells can be expanded indefinitely, overcoming the 
limitations of conventional adult muscle stem/progenitor cells. This is of particular importance for cell-
based therapies of skeletal muscle disorders, since muscle is the most abundant tissue of the human 
body, which means that large numbers of cells would be required [14]. However, for this potential to 
be fulfilled, safe and efficient differentiation protocols need to be established to derive transplantable 
skeletal muscle progenitors from these pluripotent cells. In addition, the need to produce myogenic 
cells capable of regenerating skeletal muscles of the whole body of patients affected by muscular 
dystrophy upon systemic delivery, needs to be taken into consideration. Local intramuscular cell 
delivery is not a viable option to treat systemic muscle disorders since it would require a prohibitively 
large number of injections. In this article, we review current literature and discuss the recent challenges 
and future perspectives of gene and cell therapy strategies for muscular dystrophy based upon 
pluripotent stem cells, focusing specifically on the potential of genetically corrected myogenic cells 
derived from patient-specific iPS cells for autologous transplantation. To put this into context, we will 
also summarize the most salient features of normal skeletal muscle development and muscle 
regeneration. 
 
Skeletal muscle development  
Skeletal muscle embryogenesis and regenerative myogenesis share a combination of regulatory 
pathways and transcription factors that coax myogenic differentiation [15]. An overview of muscle 
development during embryogenesis helps identify the key elements that regulate the myogenic 
program, and that serve as a basis for the development of protocols aimed at deriving myogenic 
stem/progenitor cells from pluripotent stem cells. 
In vertebrates, the skeletal muscles of the trunk and limbs originate from somites, spheres of 
paraxial mesoderm distributed in pairs on either side of the neural tube [16–19]. Cells in the somites 
acquire lineage specification from signalling molecules emanating from their surrounding micro-
environmental niche [20–22]. As somites mature they generate the dermomyotome, which contains 
multipotent cells that give rise to the skeletal muscles of the trunk and limbs. Interestingly, the head 
muscles are derived from a distinct site of origin during embryogenesis, involving distinct regulatory 
genes [23,24]. In the context of hereditary myopathies, these findings might be relevant to better 
understand the distribution of the affected muscles compared to those that escape the disease [25,15]. A 
fraction of cells of the dermomyotome will mature into the myotome, a primitive muscle structure 
containing progenitors expressing the regulatory factors myogenic differentiation 1 (MyoD) and 
myogenic factor 5 (Myf5). The remaining fraction consists of committed but undifferentiated muscle 
progenitors expressing the transcription factors paired box 3 (Pax3+) and paired box 7 (Pax7+). These 
cells will continue to proliferate without expressing differentiation markers [26–29] and will give rise 
to embryonic, fetal myoblasts and satellite cells residing in postnatal skeletal muscle [30,31]. 
The balance between cell renewal and proliferation vs. myogenic commitment and 
differentiation in vertebrate development is regulated by a hierarchical cascade of gene expression, as 
revealed by cell lineage and gene disruption studies [32]. Pax3 and Pax7 are paired-homeobox 
transcription factors that dominate myogenesis. Although Pax3 plays its role primarily during 
embryonic development and Pax7 during the later stages, the double mutant results in the loss of body 
muscles from mid-embryonic stages (E12.5) [29,28,33]. The next level in the genetic hierarchy 
controlling myogenesis is dominated by the myogenic regulatory factors MyoD, Myf5, and Myf6 
(myogenic factor 6). These factors are all important for the specification of the skeletal muscle lineage, 
as triple-mutant embryos completely lack myoblasts and skeletal muscle fibres [34]. Studies further 
support a regulatory network where Pax3 is genetically upstream of the MyoD family members 
[35,36]. Collectively, these transcriptional regulators govern skeletal myogenesis and indeed some of 
them have been successfully used in recent studies to derive myogenic progenitor cells from 
pluripotent stem cells (e.g. Pax3/7 and MyoD). 
 Adult stem cells in muscle regeneration  
Muscular dystrophies are degenerative skeletal muscle diseases characterized by repeated rounds of 
contraction-induced fibre damage [37]. These degraded fibres are replenished mainly by satellite cells; 
however, this has been shown to eventually lead to exhaustion of the resident stem cell populations [8]. 
Due to their malfunction in muscular dystrophies, and regenerative potential, therapeutic strategies 
aimed at replenishing muscle-derived adult stem cells represent a promising therapeutic avenue. 
Adult skeletal muscle regenerates after exercise, injury or disease. Satellite cells are thought to 
be the primary drivers of this regenerative capacity. Ablation of Pax7-positive satellite cells has been 
shown to lead to the progressive loss of the satellite cell lineage in skeletal muscle and to impede the 
repair of injured muscle [38–41]. However, a recent study also demonstrated efficient regeneration of 
skeletal muscle after more than 90% reduction of satellite cells following inactivation of Pax7 [42]. 
Satellite cells are mitotically quiescent in mature muscle [43] and are found in a distinct anatomical 
niche within the muscle, located next to the muscle fibre plasma membrane and underneath the basal 
lamina [1]. They express a range of characteristic, but not unique markers (reviewed in [44]). Amongst 
these markers is Pax7, which has been shown to be essential for satellite cell survival [45,46], and Pax3 
and CXCR4 (C-X-C chemokine receptor type 4), which are expressed in a subset of quiescent cells 
[33,47]. Pax7 and Pax3 transcription factors have both been shown to activate the myogenic regulatory 
factors MyoD and Myf5 [48–50]. As highlighted in the previous section, Pax3 is essential for 
embryonic development of muscle [51] but is down regulated post-natally in most muscle progenitors 
[52]. Conversely, Pax7 is not required for embryonic myogenesis but is essential for the formation of 
functional adult satellite cells [45]; although a study indicated that Pax7 was entirely dispensable in 
adult life [53], more recent evidence shows that Pax7 is critical for satellite cell function in adult 
skeletal muscle [54]. Upon muscle injury quiescent satellite cells are activated, consistent with the 
expression of Myf5 and MyoD [55]. Once satellite cells have been activated they undergo asymmetric 
division to expand a pool of committed progenitors (i.e. the myoblasts) while preserving the 
compartment of undifferentiated stem cells [56–61]. In terms of molecular markers, both quiescent and 
activated satellite cells can express Pax7, Myf5, Syndecan-3 and -4, VCAM-1 (vascular cell adhesion 
molecule 1), c-Met, Foxk1 (forkhead box protein k1), CD34, M-cadherin, caveolin-1, α 7 and l1 
integrin, CD56 and nestin. It is worth noting that some of these markers identified in mouse models do 
not fully correspond to those in human (i.e. CD34 is a marker of satellite cells in mice, but not in 
human muscle). Similarly, M-cadherin is not as consistent a marker of satellite cells in humans as it is 
in mice [62]. One of the more reliable markers of satellite cells/myoblasts in human muscle is CD56 
[63].  
 
Due to the central role of satellite cells in muscle regeneration, their use for cellular therapy 
has been thoroughly investigated. This has been outlined in detail in this issue by Sampaolesi and co-
workers, and only their most salient features will be highlighted here. Despite promising results in the 
mdx dystrophic mouse, clinical trials based on intra-muscular injection of allogeneic satellite cell-
derived myoblasts demonstrated safety but lack of efficacy [44,64]. This could possibly be ascribed to 
immune rejection, poor engraftment, low survival, inefficient migration and/or differentiation. 
However, these studies pioneered muscle stem cell transplantation in humans and the evidence of 
dystrophin production, though restricted to the injection site, is an important milestone [65]. Despite 
this setback, myoblast transplantation may be feasible for disorders that only affect a few isolated 
muscles. Indeed after promising preclinical work, a clinical trial using autologous transplantation of 
myoblasts isolated from non-affected muscles has shown promising results for oculopharingeal 
muscular dystrophy [66,67]. This opens new perspectives for localized myoblast delivery for at least 
some specific types of muscular dystrophy that manifest themselves predominantly in specific 
anatomical locations. 
To overcome the limitations of satellite cells for cell therapy, other myogenic adult 
stem/progenitor cells have been investigated (reviewed in [2]). Briefly, CD133+ cells have been shown 
to contribute to muscle regeneration in the severe combined immunodeficient (SCID)/X chromosome-
linked muscular dystrophy (mdx) mouse model for Duchenne muscular dystrophy (DMD), and pre-
clinical and preliminary clinical studies have been conducted for the treatment of DMD [68,69]. 
Recently, these cells were shown to contribute to satellite cell formation upon intramuscular injection 
into immunodeficient mice [70].  PW1+ expressing interstitial cells have been identified in the mouse as 
a subset of cells capable of contributing to new muscle fibre formation and the satellite cell pool, 
although lineage tracing experiments have shown that these cells do not share the same origin as 
satellite cells [71]. Muscle-derived stem cells (MDSC) have been shown to lead to an improved 
therapeutic outcome when administered systemically to dystrophic dogs [72].  
A subpopulation of skeletal muscle pericytes normally associated with capillaries has been 
shown to have myogenic potential. They are typically adjacent to endothelial cells and have been 
identified as the human adult tissue counterpart of mesoangioblasts [73,74]. They are a heterogeneous 
population and differ depending on their tissue of origin [75]. Lineage tracing experiments in mice 
have shown that pericytes also contribute to postnatal muscle development [73]. Importantly, 
pericytes/mesoangioblasts have been shown to contribute to muscle regeneration upon intra-arterial 
transplantation into different animal models of muscular dystrophy [76–81]. These encouraging 
findings have lead to a recently completed first-in-human phase I/II trial based upon intra-arterial 
delivery of allogeneic mesoangioblasts in five patients suffering from DMD (EudraCT no. 2011-
000176-33). A number of other myogenic progenitors have been shown to be capable of engrafting and 
differentiating into muscle fibres but a detailed description of their properties falls outside the scope of 
this review and has been described elsewhere ([2]; Sampaolesi et al., submitted). 
 
Differentiation of ES cells into muscle 
ES cells are pluripotent stem cells isolated from early embryos. They were first isolated from the inner 
cell mass of blastocyst stage mouse embryos, and their human counterpart was subsequently isolated in 
the 1990s [10,11,82]. These ground-breaking studies led to much interest in the use of these cells as a 
potential therapy. In the case of muscle disorders, this required the establishment of protocols for the 
derivation of myogenic cells, which have mostly relied on exposing the ES cells to the same factors 
that lead to myogenic commitment in the developing embryo (see above). The desired differentiated 
myogenic cells could subsequently be enriched based on the expression of specific cell surface 
markers. The main methods investigated for deriving myogenic cells from ES cells are summarised in 
Table 1. By virtue of the unlimited proliferative potential, ES cells can be expanded virtually 
indefinitely, overcoming the limitation of adult stem/progenitor cells that have a more limited 
proliferative capacity and typically undergo senescence after extensive in vitro passaging.  
  
Myosin heavy chain (MyHC)-expressing multinucleated myotubes were first derived from ES 
cells via the formation of embryoid bodies (EB) [83,84]. These are three-dimensional floating embryo-
like structures obtained from growing ES cells in the absence of a murine feeder layer. In order to 
improve myogenic differentiation, Bhagavati and Xu co-cultured EBs derived from mouse ES cells 
with a preparation made from mouse muscle that was enriched for myogenic stem and precursor cells. 
Subsequent injection of the ES derived co-cultured cells into mdx mice, resulted occasionally in the 
formation of normal, vascularized skeletal muscle of transplanted cell origin [85]. However 
engraftment was relatively inefficient, and dystrophin positive fibres were observed in only 2 out of 8 
injected mice. As an alternative route, Barberi et al. 2007 generated multipotent mesenchymal 
precursors from human ES cells which were then enriched for the CD73+ fraction to obtain cells 
capable of forming bone, fat, cartilage and skeletal muscle [86]. However as the subset of CD73+ cells 
that could form skeletal muscle was small (only 2-10%) this protocol required an additional sorting 
step for NCAM (neural cell adhesion molecule, alternative alias for CD56) and relatively long in vitro 
culture times. The ES cell-derived myogenic stem/progenitor cells obtained in these two studies had a 
lower proliferative and regenerative capacity than adult myoblasts [85,86]. This could be due at least in 
part to inefficient myogenic differentiation that resulted in the injection of a heterogeneous population 
of cells, incomplete expression of MyoD in transplanted cells or high cell death upon transplantation.  
Hence, there was a need to increase the robustness of myogenic differentiation of ES cell-derived 
myogenic cells. During normal embryogenesis and muscle regeneration, expression of the regulatory 
factor MyoD is associated with the induction of myogenic differentiation program [26,55]. Initial work 
showed that expression of MyoD was sufficient to induce myogenic differentiation in fibroblasts [87]. 
Consequently, this work justified using MyoD to also coax the myogenic differentiation of ES cells. 
Transfection of murine ES cells with MyoD cDNA led to the formation of skeletal muscle-like cells 
capable of forming contracting myotubes in vitro after EB differentiation [88,89]. However not all cells 
were converted to skeletal muscle upon MyoD expression, and the in vivo potential of these cells to 
engraft in skeletal muscle was not assessed.  
Building upon these pioneering studies, Ozasa and colleagues engineered mouse ES cells by 
including an inducible, tetracycline-regulated MyoD switch [90].  Consequently, simply culturing the 
ES cells in the absence of tetracycline can turn on the myogenic differentiation program. These ES cell-
derived differentiated cells were transplanted into mdx mice where they formed dystrophin-positive 
fibres at the injection site. However, this study did not assess long-term engraftment, and tumour 
formation was noted upon injection into immunodeficient mdx mice due to the presence of 
undifferentiated cells. In an attempt to further improve the efficiency of myogenic derivation from ES 
cells, they were genetically modified with an alternative genetic switch based on doxycycline-inducible 
expression of either Pax3 or Pax7 [91,92]. Myogenic cells were obtained by transient induction of 
either Pax3 or Pax7 expression during EB growth. Initial injection of these cells resulted in teratoma 
formation (tumours with cell derivatives originating from more than one germ layer) due to the 
presence of non-myogenic committed cells. Subsequently the authors used fluorescence activated cell 
sorting (FACS) to isolate platelet-derived growth factor- receptor positive (PDGF-αR+) fetal liver 
kinase 1 negative (Flk-1-) cells. PDGF-R and Flk-1 are expressed in unpatterned embryonic 
mesoderm, with subsequent Flk-1 down regulation specifying paraxial mesoderm, hence the authors 
hypothesised that by sorting for these markers they would isolate a population of myogenic precursor 
cells. These ES-derived myogenic cells exhibited relatively robust engraftment, differentiation and 
significant improvement in muscle force generation [91–93]. This method demonstrated improved 
contractile properties when mouse cells were injected systemically into dystrophic mdx mice [91,92] 
and was also adapted using other myogenic regulators downstream of Pax3/7 such as Myf5 [94].  
In a similar study, Sakurai and colleagues generated ES-derived muscle-like cells after FACS 
enrichment of PDGF-R+ cells but this time without relying on genetic modification with myogenic 
regulatory genes [95]. However whether these cells are capable of leading to a functional improvement 
similar to the results seen with the Pax3/Pax7 induced cells, or if they are capable of muscle 
engraftment following systemic delivery, needs to be further investigated. Alternatively, satellite-like 
myogenic cells could be derived from ES cells using an EB-based protocol followed by FACS 
enrichment of SM/C-2.6+ cells [96]. SM/C-2.6 is an antibody that detects murine quiescent satellite 
cells, however the exact antigen that this antibody is recognising is unknown [97]. Intramuscular 
injection into cardiotoxin-injured mice contributed to repair of muscle damage after primary and 
secondary injury, and after serial transplantation. However, whether this muscle repair is sufficient to 
lead to functional improvement remains to be assessed. Additionally, although these results are 
promising, it is worth noting that the SM/C-2.6 antibody protocol is not directly applicable to human 
ES/iPS cells, as this antibody has only been shown to be specific for murine satellite cells.  Finally, the 
conditioning regimen based upon cardiotoxin is clinically not relevant and only serves as a model to 
facilitate engraftment of the myogenic progenitors.   
Recent promising work has developed further transgene free methods to drive myogenic 
differentiation, this time using small molecules to act on key signalling pathways. Shelton and 
colleagues used treatment with a WNT agonist, glycogen synthase kinase 3 (GSK-3) inhibitor, to 
obtain paraxial mesoderm and Pax3+ premyogenic mesoderm in human and mouse ES cells [98]. 
Subsequent treatment with basic fibroblast growth factor (bFGF) was used to expand myogenic 
progenitor cells, followed by N2 treatment to induce terminal differentiation. This protocol used 
transgene-free, serum-free and chemically-defined methods; however, it requires relatively long in 
vitro culture times (40- 50 days) to obtain myocytes and myotubes. Additionally, the in vivo potential 
of these cells to engraft in muscle remains to be assessed. Although commitment to the myogenic 
lineage was efficient, it did not occur in the entire population of cells, so further cell sorting steps 
maybe required before in vivo transplantation.  
Recently, a few laboratories have focused their efforts to induce direct MyoD-mediated myogenic 
conversion of pluripotent cells without intermediate commitment steps (e.g. mesodermal transition). In 
this context Puri and co-workers elegantly showed that absence of the SWI/SNF component BAF60C 
induces human ES cell resistance to direct MyoD-mediated activation of skeletal myogenesis. 
Expression of BAF60C activated skeletal myogenesis in human ES cells by instructing MyoD 
recruitment and chromatin remodeling at target genes [99]. This finding supports the model that 
MyoD-mediated myogenic conversion is indeed a complex process normally requiring cells in a 
permissive state in order to respond efficiently (i.e. differentiate), rather than a non-specific process 
whereby a dominant factor converts all cells to the muscle lineage irrespective of their origin or 
proximity to the mesoderm and myogenic program.  Initial evidence supporting this model, such as 
very low frequency (or absence) of myogenic conversion in response to MyoD expression in some cell 
lines/lineages can indeed be traced back to seminal papers in the field of myogenic regulators and 
trans-differentiation [87,100,101].  
 
Though these studies indicate the potential of ES cells to obtain myogenic precursor/stem cells 
that could be used for muscle regeneration in vivo, there are still some limitations that preclude their 
potential clinical use. In particular, there are ethical concerns over the use of ES cells as they are 
derived from, and result in the destruction of, human embryos. Nevertheless, there is an ethical 
framework that potentially allows for the use embryos resulting from in vitro fertilization programs that 
will not be re-implanted. Furthermore, recent work has shown that it maybe possible to derive human 
ES lines from a single cell biopsy of an eight cell in vitro fertilised embryo without its subsequent loss 
[102]. However, despite this promising work certain intrinsic ethical concerns over the cloning of cells 
from human embryos will still remain for many individuals [103]. Additionally, as these cells are 
indeed derived from human embryos they cannot by definition be patient-specific, and therefore 
autologous transplantation is not possible raising immune concerns (as detailed in the section iPS 
versus ES derived myogenic stem cells). Moreover, there are important safety concerns regarding the 
persistence of residual undifferentiated ES cells that could eventually give rise to teratomas and/or the 
intrinsic genetic instability of ES cells, that may perturb cellular proliferation, survival and/or 
differentiation. In general, there is still a need to increase the robustness of system-wide phenotypic 
correction in the afflicted muscle groups in dystrophic animal models by intra-vascular administration 
of ES-derived myogenic progenitors. This is compounded by the clearance of the ES-derived myogenic 
progenitors by the reticulo-endothelial system. Ultimately, it would be reassuring to have safety and 
efficacy data in large animal models but this is far more challenging than the initial proof of concept 
studies in mdx mouse models described above. Despite these caveats, these pioneering studies in ES 
cell research have laid the groundwork for the use of iPS cells in regenerative medicine application for 
degenerative muscle disorders. 
 
Differentiation of iPS cells into muscle 
The discovery of protocols to reprogram adult cells into a pluripotent embryonic-like state 
revolutionized stem cell biology and regenerative medicine [104]. Reprogramming was achieved by the 
integration of four reprogramming factors: octamer-binding transcription factor 4 (Oct4), kruppel-like 
factor 4 (Klf4), sex determining region Y-box 2 (Sox2) and c-Myc. These reprogramming genes need 
to be transiently expressed during a critical window, after which their transcription is repressed by 
epigenetic mechanisms. The maintenance of the pluripotency of these cells in vitro is carefully 
controlled by exposure to specific culture parameters, with the recent formulation of xenofree, 
chemically defined media and substrate [105], which will facilitate the clinical translation of these cells 
and the establishment of GMP/GLP protocols. Pluripotency is lost when the cells are exposed to 
different culture conditions and signalling molecules, and when injected into immunocompromised 
mice undifferentiated iPS cells undergo spontaneous uncontrolled differentiation giving rise to 
teratomas [106]. Recently these results have also shown to be true for autologous iPS cells in non 
human primate models, however iPS cell derivatives did not demonstrate any tumour formation [107].  
 
To ensure that ES/iPS cell-derived myogenic progenitor/stem cells function normally in vivo after 
transplantation into the host, they would need to optimally integrate with the skeletal myofibres and, 
ideally, within the satellite cell niche. This is a defined anatomical niche along the surface of muscle 
fibres under the basal lamina that plays an important role in controlling muscle satellite cell self-
renewal and differentiation (reviewed in [108–110]). Consequently, this skeletal muscle niche will be 
equally important for controlling the self-renewal and differentiation of the myogenic ES/iPS cell 
progeny. Based largely on studies with satellite cells, there are several components of the skeletal 
muscle niche that would need to be considered to optimally regulate the function of ES/iPS cell 
derivatives: (i) the host muscle fibre greatly influences the function of muscle stem/progenitor cells 
through mechanical, electrical, and chemical signals; (ii) the basal lamina, a layer of extracellular 
matrix (ECM) that consists mainly of laminin, proteoglycans and collagen. The maintenance of stem 
cell identity likely requires anchoring to this basal lamina; (iii) the microvasculature to ensure optimal 
blood supply, and interstitial cells (e.g. macrophages, fibroblasts). These distinctive features of the 
skeletal muscle niche therefore suggest that a combination of signals from the host muscle fibre, 
circulation system and ECM will likely be important control the quiescence, activation, and 
proliferation of both satellite cells and ES/iPS cell derivatives. 
 
 Transplantation of human ES/iPS-derived myogenic stem cells in immunodeficient mice has its merits 
and permits assessment of their safety and efficacy profiles. Nevertheless, murine and human muscle 
stem/progenitor cells are intrinsically different, consistent with their differential expression pattern of 
specific muscle markers (e.g. SM/C 2.6) [97]. Consequently, preclinical studies based on murine 
muscle stem/progenitor cells -or their cognate myogenic ES/iPS cell derivatives- may not necessarily 
replicate all of the features of their human counterparts in a clinical setting. This may reflect species-
specific differences in survival, migration and differentiation that depend largely on the interaction of 
the transplanted cells with the host micro-environment [111]. To overcome these limitations, three-
dimensional biomimetic models of human skeletal muscle are being generated in vitro to resemble as 
much as possible the in vivo environment [112–114]. Synthetic scaffolds and decellularised devices 
from large animal models could ultimately be used to optimise stem cell maturation, differentiation and 
engraftment of ES/iPS-derived myogenic cells towards possible clinical applications. 
 
iPS cells circumvent the ethical concerns of using ES cells since they can be derived from virtually any 
somatic cells, without the involvement of human embryos. Moreover, patient-specific iPS cell 
derivation opens new perspectives for autologous transplantation, as it should avoid immune rejection. 
However, in the case of using iPS cell derivatives to treat inherited disorders, such as muscular 
dystrophies, the underlying genetic defect would need to be corrected first by ex vivo gene therapy 
prior to transplantation. iPS cells are also well suited as an in vitro cellular platform for disease 
modelling and drug screening [115]. Another advantage of using iPS cell-derived cells over adult 
myogenic stem/progenitor cells is their unlimited proliferation capacity, as in the case of ES cells.  
Consequently, the generation of iPS cells requires only a limited number of patient cells, avoiding 
invasive procedure as in the case of adult stem/progenitor cells. Typically, this has been achieved 
through the reprogramming of fibroblasts isolated from minimally invasive skin punch biopsies and 
recent reports have successfully achieved similar results using cells isolated from blood or urine 
[116,117]. However, there is evidence that the origin of the cells used to generate iPS cells might bias 
the differentiation efficiency, in favour of the lineage of the donor somatic cell type (reviewed in 
[118,119]). This likely reflects an ‘epigenetic memory’ of the cell type of origin that is not fully reset 
during the reprogramming process. Indeed, this has been shown to be the case for iPS cells derived 
from mouse myogenic cells versus fibroblasts [120] and human cardiac versus non-cardiac cells [121]. 
Though the long-term consequences of this epigenetic memory on pluripotency, safety, cell survival 
and differentiation are not fully understood, it may facilitate coaxed differentiation of iPS cells into the 
desired cell type. Nevertheless, robust skeletal myogenic differentiation protocols may potentially over-
ride the effects of epigenetic memory on differentiation bias [9]. For ultimate clinical translation it 
might be worthwhile standardising the tissue of origin of the reprogrammed cell type, to minimize 
variation in myogenic differentiation efficiencies and safety profiles. 
 
iPS cells have initially been derived by retroviral vector-mediated integration of the 
reprogramming cassettes. Though very effective, this approach carries an intrinsic risk of insertional 
oncogenesis [122]. Furthermore, some of the reprogramming factors are de facto oncogenic and their 
re-expression from the integrated reprogramming cassette cannot be excluded. However, potentially 
safer alternative reprogramming paradigms have been developed that rely on non-integrating vectors, 
protein transduction or ‘transgene-free’ reprogramming during which the reprogramming cassette is 
episomal or subsequently excised from the iPS genome [123,124]. Recent studies in non-human 
primates have laid the foundation for the first-in-man iPS pilot study to assess the safety of using 
patient-derived iPS cells for the treatment of an eye disorder, age-related macular degeneration 
[107,125–127]. This pilot clinical study is likely to generate critically important information towards 
extending iPS cell-based clinical protocols to other tissues and diseases.  
As with ES cells, the use of iPS cells for the treatment of degenerative muscle disorders 
requires the establishment of protocols for their efficient directed differentiation into myogenic cells. 
Coaxed differentiation of iPS cells into muscle-like cells has mainly been achieved by applying similar 
techniques that were initially validated in ES cells. These methods are summarised in Table 2, and are 
discussed in more depth below. 
 
Inducing myogenic differentiation of iPS cells using a Pax3 or Pax7 genetic switch 
To coax myogenic differentiation of murine or human iPS cells, they have been genetically modified to 
contain a genetic switch that uses doxycycline-inducible expression of Pax7 during EB differentiation, 
followed by FACS enrichment for PDGF-R+Flk-1- cells, or for co-expression of the green 
fluorescent protein GFP (where GFP is co-transfected/expressed with Pax7) [93,128], as described 
above in ES cells [91,92]. As with the previous studies, no tumour formation was observed in 
transplanted mice. Functional improvement as measured by isometric tetanic force, long-term 
engraftment and restoration of dystrophin expression was noted upon intramuscular transplantation of 
these cells into cardiotoxin injured dystrophic mice. Our studies were consistent with these findings, 
and showed that transposon-mediated Pax3 gene transfer in murine iPS cells coaxed their 
differentiation into multinucleated MyoD+MyHC+ myotubes [129]. Similarly, a doxycycline-inducible 
Pax3 genetic switch was used to derive murine iPS cells from mice who were double knockouts for 
dystrophin and utrophin [130]. These iPS cell-derived myogenic cells were also able to engraft skeletal 
muscle of double knockout mice for dystrophin and utrophin upon systemic intravenous (IV) delivery. 
However, significant pre-clinical toxicity studies would be necessary to support possible clinical 
translation of this strategy, as it is not clear what mechanism would prevent the accumulation of IV-
delivered cells in filter organs, including the lungs.  
 
Inducing myogenic differentiation of iPS cells using a MyoD switch 
MyoD expression is thought to generate a pool of transient-amplifying progenitors at the expense of 
undifferentiated stem cells; this is a consequence of its role in myogenic commitment. However, it was 
also reported that a significant number of MyoD-negative satellite cells derive from MyoD-positive 
parents, supporting the idea that MyoD expression does not necessarily result in terminal 
differentiation and implying a mechanism to bring cells back to a stem/precursor state even after MyoD 
expression [61]. Furthermore, we have also reported the generation of donor-derived sublaminar Pax7-
positive cells in SCID/mdx muscles transplanted with genetically-corrected mouse mesoangioblasts 
that also expressed a MyoD transgene [80]. Based upon this evidence and to overcome the limited 
availability of muscle pericytes in patients with limb-girdle muscular dystrophy 2D (LGMD2D), we 
developed a protocol to differentiate human iPS cells into pericyte/mesoangioblast-like progenitors that 
can be expanded in culture (designated as HIDEMs: human iPS-derived mesoangioblast-like cells). To 
achieve this, a stepwise mesodermal differentiation protocol was employed that does not rely on EB 
formation and requires no additional FACS purification steps [9,131]. HIDEMs were genetically 
corrected (as detailed in the section Ex vivo gene therapy using genetically corrected iPS cells) and 
then transduced with a lentiviral vector encoding a chimeric, tamoxifen-inducible MyoD-ER(T) 
(estrogen receptor). Specifically, in the presence of tamoxifen MyoD-ER is translocated to the nucleus 
where it initiates the myogenic differentiation program. Consequently, myogenic differentiation of the 
HIDEMs could be accomplished in vitro or in vivo after transplantation into immune-deficient 
dystrophic mice in a tamoxifen-dependent manner [132]. In support of the safety of this differentiation 
protocol, we showed that HIDEMs were not tumorigenic in vivo.  
An alternative MyoD-based approach was used to differentiate DMD iPS cells [133]. Cells 
were cultured in myogenic medium to induce mesenchymal differentiation, after which they were 
transduced with an adenoviral vector expressing MyoD. The iPS cell-derived progenitors were capable 
of generating multinucleated myotubes in vitro, and upon transplantation into the immunodeficient and 
dystrophic RAG/mdx mice participated in muscle regeneration. However, potential immunogenicity 
issues related to the use of adenoviral vectors might limit the application of this strategy.  
A MyoD inducible system was also used for myogenic differentiation of human iPS cells from 
patients with Miyoshi myopathy (MM), an inherited muscular dystrophy caused by dysferlin 
mutations, and for carnitine palmitoyltransferase II deficiency, an inherited myopathy caused by 
mutations in CPT2 [134,135]. This inducible MyoD method differs from those used by us and by 
Goudenege et al., in that the doxycycline inducible MyoD is transposed directly into the 
undifferentiated iPS cells. Resulting human MyoD-iPS cells were able to undergo direct myogenic 
differentiation without a mesodermal transition step (10 days), however the in vivo regenerative 
potential of the myogenic cells derived using this method remains to be determined. Finally, Abujarour 
and colleagues also reported direct MyoD-mediated differentiation of iPS cells into myocytes in vitro 
without the need for an intermediate step or cell sorting [136]. Although relatively faster than other 
methods, these strategies appear to be more suitable for drug screening than for gene therapy 
applications. Indeed genetic correction of pluripotent colonies is technically challenging and the 
absence of an expandable myogenic cell might limit banking and standardization of a possible cellular 
medicinal product. 
 
Inducing myogenic differentiation of iPS cells without genetic modification 
Satellite-like myogenic cells were derived from murine iPS cells using an EB-based protocol followed 
by FACS enrichment of SM/C-2.6+ cells that was initially developed for ES cells [96,137].  A similar 
step-wise EB-based protocol was used to obtain myogenic cells from human ES and iPS cells, which 
included EB formation followed by dissociation and culture on collagen type-I coated plates with 
serum containing medium [138]. In this case, there was no enrichment step based on the use of anti-
SM/C-2.6 antibodies since they do not bind on human cells.  An advantage of these differentiation 
protocols is that they did not require genetic modification with genes encoding myogenic 
differentiation factors. However, it required relatively prolonged in vitro culture times, 49 days to 
obtain myogenic precursors used in transplantation studies and 63 days for the in vitro formation of 
mature myotubes, and myogenic induction was not very efficient.  
Recently Borchin et al 2013 developed an alternative method that does not rely on genetic 
modification to generate muscle precursors from iPS cells [139]. Paraxial mesoderm was derived from 
human ES cells and iPS cells by treating cells with a GSK-3β inhibitor, and myogenic cells were 
subsequently expanded by the addition of bFGF. In order to obtain a pure Pax3+/Pax7+ population, 
myogenic cells were subsequently sorted for the chemokine receptor CXCR4 and hepatocyte growth 
factor receptor C-MET/HGF, where as sorting for the muscle-specific acetylcholine receptor was used 
to obtain mature skeletal myocytes. However the therapeutic potential of these cells has not yet been 
tested in vivo. 
To identify small molecules capable of promoting myogenesis, Xu and colleagues performed 
a high-throughput screening to test the ability of 2400 compounds to promote myogenesis in zebrafish 
embryos [140]. As a result of this screening, the authors identified a ‘triple cocktail’ of bFGF, the 
adenylyl cyclase activator forskolin, and the GSK-3 inhibitor BIO that could promote skeletal muscle 
differentiation when applied to EBs derived from human iPS cells. The resulting cells were also 
transplanted by intramuscular injection into immunodeficient mice, where they engrafted skeletal 
muscle. No tumour formation was observed. Although this does not require transgene insertion, the 
authors did not provide evidence of genetic manipulation/correction of the cells, engraftment in 
dystrophic muscle or test systemic delivery of these cells.  
 
iPS versus ES derived myogenic stem cells 
A head-to-head comparison between human ES and iPS-derived myogenic stem cells [93] did not 
reveal any major differences in terms of phenotypic markers or functional attributes, including their 
regenerative potential, engraftment efficiency, functional recovery and contributions to the satellite cell 
pool. Similarly, using a distinct differentiation protocol, both human iPS and human ES-derived 
mesoangioblast-like cells could be obtained, with similar properties [131]. It would therefore appear 
that under the same differentiation conditions, the myogenic progenies derived from either ES or iPS 
cells show similar myogenic potential in vitro and regenerative capability in vivo. This further supports 
the use of iPS cell-derived muscle stem cells as an adequate alternative to ES cell derivatives for future 
clinical applications. Similarly, other human ES and iPS cell-derived cell types (i.e. neural, hepatic, and 
mesenchymal lineages) are nearly equivalent transcriptionally [141]. Though transcriptome analysis of 
iPS and ES cells revealed some differences [142], this type of comparisons has never been made 
between cells obtained from the same individual.  Consequently, inter-individual variations cannot be 
excluded. 
 
Another aspect to consider in order to use ES/iPS cell-derived myogenic cells in a clinical setting, 
concerns their possible immune-modulatory properties. ES cells are de facto allogeneic. Consequently, 
any ES cell-based cell therapy would require immune suppression to minimize the risk of inadvertent 
immune responses that would reject the ES-derived cells after transplantation. This is compounded by 
the increase in immunogenicity during differentiation of ES cells [143,144]. In another study, it was 
shown that proliferating myogenic progenitors derived from mouse ES (or iPS) cells express major 
histocompatibility complex (MHC) class I molecules [93]. Elevated MHC class I expression is known 
to increase their sensitivity towards cytotoxic T cells (CTL) but also suppress natural killer (NK) cell-
mediated immune response [145]. 
 
 Since iPS cells are typically obtained from autologous somatic cells, it was assumed that this would 
obviate immune concerns after transplantation of its differentiated iPS cell-derived progeny. However, 
since syngeneic mouse iPS cells have been rejected following transplantation in vivo into mice, this 
indicates that even autologous iPS cells can be recognised by the immune system [146]. Hence, the 
immunogenicity of iPS cells and their derivatives would need to be carefully examined. Nevertheless, 
analysis of the interaction between human iPS cell-derived mesoangioblasts (HIDEMs) and immune 
cells suggests a reduced risk of evoking potential immune responses [147]. Indeed, HIDEMs suppress 
T cell proliferation through IDO and PGE-2 dependent pathways, consistent with the results from 
tissue-derived mesoangioblasts [148]. 
 
 The remarkable similarity between HIDEMs and their tissue-derived counterpart, together with the 
recent completion of a clinical trial based upon the transplantation of human pericyte-derived 
mesoangioblasts, could facilitate future clinical translation of this cell type. Ideally, an autologous, 
personalized cell therapy could be envisaged, where patient-specific iPS cells or myogenic derivatives 
are genetically corrected first and subsequently transplanted into the same patient. Nevertheless, an 
allogeneic cell transplant could also be considered, whereby muscle-like cells derived from iPS cells of 
a healthy donor would be transplanted into an HLA-matched recipient [149]. This would require 
immune suppression, as in the case where tissue-derived allogeneic mesoangioblasts or other muscle 
stem/progenitor cells were employed. Regardless of the immune response against the transplanted 
cells, it cannot be excluded that the therapeutic protein itself may provoke an immune reaction. 
 
 The use of regulatory T cells (Treg), capable of suppressing or “regulating” the activation of 
alloreactive lymphocytes [150] represents an alternative strategy that could potentially be exploited to 
limit alloreactive and/or transgene-specific immune reactions in the context of cell/gene therapy with 
iPS or ES-derived muscle cells. Interestingly, a particular Treg subtype was enriched in muscle upon 
acute or chronic injury, and promotes tissue repair in vivo [151]. The possibility to reinforce immune 
tolerance induction by potentiating Treg activity is an attractive possibility to foster transplant graft 
acceptance, including that of ES/iPS cell-derived cells [152]. Further studies are needed to investigate 
the immune consequences of ES/iPS cell-derived myogenic cells in vivo to ensure stable cell 
engraftment in inflamed muscles. 
 
Ex vivo gene therapy using genetically corrected iPS cells   
The development of iPS cell technology in combination with advanced gene therapy methods offers a 
unique scenario for the treatment of genetic diseases by ex vivo gene therapy, moving closer to the 
prospect of an autologous and personalized cell therapy. This approach consists of isolating cells from 
the patient, modifying them in the laboratory, and then transplanting them back into the very same 
patient, an overview of this potential approach is summarised in Figure 1. The genetic modification is 
based either on the introduction de novo of a functional copy of the therapeutic gene  (i.e. ‘gene 
addition’) or on in situ targeted correction of the defective gene (i.e. ‘genome editing’) in the iPS cell 
colonies or derivatives.  Several gene transfer technologies have been developed that were used to 
genetically modify iPS cells and/or their differentiated progeny. Most importantly, to be effective, the 
genetic modification needs to be stably transmitted to the iPS cell progeny.  Consequently, gene 
addition has typically been achieved using integrating vector platforms (i.e. transposon, retroviral or 
lentiviral vectors) or stably persisting episomes such as human artificial chromosomes (HACs). In 
contrast, specific targeted gene correction by genome editing requires the use of engineered designer 
nucleases that enhance homology-directed gene repair 104 to 105-fold by inducing a double-strand 
DNA break at the genomic target locus.  The most commonly used designer nucleases are based on the 
zinc finger nuclease (ZFN) transcription-activator like effector nuclease (TALEN) and, more recently, 
clustered regularly interspaced short palindromic repeat (CRISPR/Cas9) platforms.  Whereas targeted 
gene correction by gene editing is specifically tailored towards specific mutations in the target gene and 
thus specific patient sub-populations harbouring these mutations, gene addition is widely applicable 
irrespective of the underlying genotype. 
 
  
Gene addition 
In 2012 we provided the first evidence of successful ex vivo gene therapy using patient-specific 
differentiated iPS cells for a muscle disorder. Specifically, limb-girdle muscular dystrophy 2D 
(LGMD2D) iPS cell-derived inducible myogenic cells (HIDEMs) were genetically corrected with a 
lentiviral vector encoding the human α-sarcoglycan gene (whose mutations cause LGMD2D) under a 
muscle specific-promoter and then also transduced with another lentiviral vector encoding a MyoD-
ER(T) transgene as a myogenic differentiation switch, as described above. Genetically corrected 
LGMD2D HIDEMs were successfully transplanted intramuscularly and intra-arterially into α-
sarcoglycan-null immunodeficient (Sgca-null/scid/beige) mice, a preclinical model of LGDM2D, and 
produced α-sarcoglycan-positive muscle fibres that were detectable one month post transplantation [9]. 
Consequently, de novo expression of the missing α -sarcoglycan led to the reconstitution of the 
dystrophin-associated protein complex in host myofibres. Similarly, species-specific transplantation of 
mouse iPS cell-derived progenitors in Sgca-null/scid/beige mice led to robust engraftment of large 
areas of host muscle, re-establishment of muscle pericytes in vivo and functional amelioration of the 
dystrophic phenotype. This proof of concept study established the validity of an autologous gene 
therapy approach for the treatment of LGMD2D, and possibly other forms of muscular dystrophy, 
based upon transplantable iPS cell-derived myogenic cells. Indeed, the same protocol allowed the 
generation of HIDEMs also from DMD iPS cells, which were genetically corrected with a HAC 
containing the entire dystrophin genetic locus (DYS-HAC) [9,153]. This stably maintained, episomal 
DYS-HAC accommodates the entire genomic dystrophin locus (2.4 Mb) avoiding integration-
associated risks. Furthermore, such delivery of the entire gene is mutation independent, thus ensuring 
applicability to the variety of mutations/duplications/deletions that cause DMD.  
A different approach for the treatment of DMD has been proposed by Filareto et al., where the 
dystrophic phenotype of dystrophin/utrophin null mouse iPS cells was corrected by providing micro-
utrophin (µUTRN) with a non viral vector Sleeping Beauty transposon [130].  Utrophin is a protein 
closely related to dystrophin, whose over expression has been shown to ameliorate the dystrophic 
phenotype in mdx mice [154]. In order to achieve myogenic differentiation Filareto et al. used Pax3 
induction and sorting for PDGFαR+/Flk1- expression. Subsequently, the genetically corrected 
myogenic cells were transplanted in dystrophin/utrophin null mice where contribution to muscle 
regeneration and improvement in contractility were achieved. This study does not represent 
dytrophin/DMD gene correction sensu stricto, as the defective dystrophin is replaced by utrophin; 
importantly, this strategy is so far limited to mouse iPS cells and data supporting its validity using 
DMD iPS cells will be necessary in order to consider potential clinical translation.   
By using a similar gene transfer approach, in the work of Tanaka et al. correction of human 
iPS cells derived from patients affected by Myoshi myopathy (MM) was achieved by providing the 
full-length dysferlin (DYSF) transgene using the piggyBac transposon system [134]. Restoration of 
expression of the missing protein has been detected in vitro on the membrane of genetically corrected 
MM human iPS cell derived myotubes. Moreover the transgenic expression of full-length DYSF 
rescued the MM phenotype, as demonstrated by an improvement in the defective membrane repair 
phenotype of MM myotubes during in vitro functional tests such as two-photon laser-induced injury of 
the sarcolemma. Transplantation in MM animal models is expected to move this strategy forward. 
Despite the previously mentioned studies that have demonstrated the validity of using transposons as a 
tool to genetically correct iPS cells derived from patients with muscular dystrophies, their use has yet 
to be explored for the delivery to patient iPS cells of larger transgene such as the full-length dystrophin. 
Furthermore, extensive analysis must be conducted to delineate the integration profile of transposons in 
iPS cells in order to exclude the risk of insertional mutagenesis and move towards clinical applications. 
 
Targeted gene editing 
The use of designer nucleases such as ZFNs, TALENs and CRISPR/Cas9 allows for efficient targeted 
gene correction of the dystrophin locus in iPS cells and/or myogenic progenitor cells and therefore 
provides an attractive alternative to the aforementioned gene addition strategies. These powerful 
genome engineering tools have shown great effectiveness for the correction of disease mutations in iPS 
cells for several diseases such as ß-thalassemia [155], α1-antitrypsin deficiency [156] and 
epidermolysis bullosa [157]. In a recent work, neural stem cells (NSCs) generated from iPS cells of 
myotonic dystrophy type 1 (DM1) patients were corrected in vitro by TALEN-mediated homologous 
recombination (HR) [158]. These results provide the first proof-of-principle evidence that TALENs 
may be used to generate genetically modified DM1 progenitor cells as a first step toward autologous 
cell transfer therapy for DM1. An extension of this approach to revert a possible muscle phenotype of 
DM1 iPS cell-derived myogenic progenitors might be considered as a promising area of investigation. 
In the case of DMD, proof-of-concept had been established by Gersbach and colleagues, who 
demonstrated correction of the dystrophin open reading frame using TALENs specifically design to 
target and edit the dystrophin exon 51 locus [159]. This led to restoration of dystrophin protein 
expression in DMD skeletal myoblasts and dermal fibroblasts that were reprogrammed to the myogenic 
lineage by forced expression of MyoD.  There was no evidence of off-target effects based on exome 
sequencing of in silico predicted target sites, suggesting that TALEN-mediated genome editing was 
highly specific for the target locus.  An alternative approach was based on ZFNs that were specifically 
designed to permanently remove essential splicing sequences in exon 51 of the dystrophin gene and 
thereby exclude exon 51 from the resulting dystrophin transcript [160]. DMD myoblasts engineered 
using these designer ZFNs contained the expected deletion of exon 51 resulting in concomitant 
restoration of dystrophin protein expression. Furthermore, transplantation of the ZFN-corrected 
myoblasts into immunodeficient mice resulted in human dystrophin expression in vivo. This provides 
an attractive alternative to oligonucleotide-induced exon skipping to permanently and irreversibly 
restore the dystrophin reading frame and protein production, obviating the need for continuous drug 
administration. One caveat of these proof-of-concept studies is that they are based on DMD myoblasts, 
which are not ideally suited for cell therapy in DMD patients based on their limited proliferation 
potential and inability to efficiently migrate out of the blood stream following their systemic 
intravascular administration.  
In a recent study, a multiplex CRISPR/Cas9-based gene editing system has been designed to 
restore the dystrophin reading frame in DMD myoblasts by targeting the mutational hotspot at exons 
45–55 [161]. Although this approach has the advantage to correct potentially more than 60% of DMD 
patient mutations with a single genome-editing strategy, the final product is a shorter version of the 
human dystrophin. In another study, instead, the specificity of the TALEN/CRISPR gene editing 
system for mutations/deletions in the dystrophin gene that lead to a lack of exon 44 has been explored 
to restore the expression of the full-length human dystrophin in DMD patient-derived iPS cells [162]. 
The high specificity of the nuclease design was done after a comprehensive genome-wide mutation 
analyses to assess the risk of off-target mutagenesis in DMD iPS cell clones treated according to the 
TALEN or CRISPR approach. By using three different methods, they demonstrated the genetic 
correction of the dystrophin gene in patient-derived iPS cells. The first of these methods restored the 
reading frame via disruption of the splice sites leading skipping of exon 45, the second introduced 
small indels (insertions or deletions); and the third used ‘knock-in’ of the missing exon 44 in front of 
exon 45 to restore the full protein coding region. Although restoration of dystrophin expression was 
detected in all of the three different genetically corrected iPS cells differentiated into myogenic cells, 
only the exon knock-in approach restored the full-length rather than truncated (i.e. lacking exon 44 or 
44-45) dystrophin protein. These encouraging results pave the way towards an ex vivo designer 
nuclease-based gene therapy approach using patient-specific human iPS cells. Efficient functional 
correction of the dystrophic phenotypic in vivo would still need to be demonstrated. One caveat of 
these gene editing approaches is that their overall efficiency is not as high as with more conventional 
gene addition strategies but incremental changes in technology may eventually overcome this.  
 
TRANSLATIONAL CHALLENGES AND CONCLUDING REMARKS 
The clinical translation of iPS cells for the autologous gene and cell therapy of genetic diseases 
represents perhaps one of the greatest challenges of modern molecular medicine. Even though this 
process may benefit from the knowledge acquired to translate viral vectors into new therapeutics 
[163,164], several hurdles are being (or will need to be) addressed to successfully complete this 
process, including: possible genome instability, residual undifferentiated tumorigenic cells, large scale 
production under GMP/GLP grade regulations, preservation of self-renewing potential, epigenetic 
memory of the cells of origin and re-expression of potentially oncogenic reprogramming factors (e.g. 
Myc). In the case of skeletal muscle and its diseases, this also needs to be considered in the context of 
other tissue-specific obstacles, including the need to target the diaphragm and the heart in order to 
counteract the cardiac and respiratory failure that underline several forms of muscular dystrophy (e.g. 
DMD).  
 
Pluripotent stem cells offer the invaluable prospect of obtaining an unlimited number of cells for 
regenerative therapies, which is vital for the treatment of muscular dystrophies (skeletal muscle being 
the most abundant human tissue). Indeed recent clinical studies highlight the need to use large number 
of cells to treat dystrophic patients, the amount of cells and their delivery depending primarily on the 
type of cells and disorder. Local transplantation of autologous myoblasts in the pharyngeal muscles of 
OPMD patients showed that improvements in both swallowing and quality of life were observed in 
patients who had been injected with more than 178 million cells [67]. On the other hand, to test the 
safety of allogeneic transplantation of mesoangioblasts in DMD children the average amount of 
transplanted cells was in the order of 109 per patient. Then, to reach clinical efficacy, it is expected that 
a dose of cells significantly higher than this would be required. Transplanted cell engraftment and 
contribution to host myofibres are key issues to face in cell therapy. Satellite cell long-lasting self-
renewal has been showed for up to 7 rounds of transplantation with as little as 16 cells [58]. These 
findings support the idea that for a successful cell therapy, the self-renewal potential of the donor cells 
might be as important as their capability to be expanded extensively. 
 
Further studies are needed to optimise genome-integration- and animal-component- free 
protocols that can be used for the large-scale production of iPS cells, and for the derivation/purification 
of myogenic cells from iPS cells under GMP/GLP conditions. Moreover, new chemically-defined 
methods should also focus on obtaining myogenic progenitors able to migrate and engraft into muscles 
upon loco-regional/systemic delivery, thus improving the likelihood of efficacy of such therapies.  
Different vectors have been exploited for the ex vivo correction of patient/disease-specific iPS 
cells. Theoretically the most valuable of the studied gene therapy approaches are those able to provide 
functional expression of the missing gene irrespective of the underlying mutation, and will thus be 
applicable to a larger number of patients. However, the recent introduction of fast and cost-effective 
CRISPR/Cas9-based gene editing platform might also shift this paradigm toward a more “a la carte” 
personalised approach. Furthermore, for safe ex vivo genetic correction the risk of vector-induced 
immune responses needs to be thoroughly investigated, and the danger of insertional mutagenesis 
avoided either through the use of site-specific integration or non-integrating systems that are stably 
maintained.  
In conclusion, emerging methods for the generation and genetic correction of pluripotent stem 
cells and their myogenic derivatives have an extraordinary potential for the cell therapy of muscle 
disorders, and many encouraging initial results have been described in this review. We believe that the 
recent effort to translate iPS cells into medicinal products for cell therapies [125–127] may provide 
invaluable insights for the future challenge of autologous iPS cell-based therapies for muscle diseases. 
 
LIST OF ABBREVIATIONS 
bFGF = basic fibroblast growth factor 
Cas9 = clustered regularly interspaced short palindromic repeat associated 9  
C-MET/HGF = hepatocyte growth factor c MET receptor 
CRISPR = clustered regularly interspaced short palindromic repeat 
CTL = cytotoxic T cells 
CXCR4 = C-X-C chemokine receptor type 4 
DM1 = myotonic dystrophy type 1 
DMD = Duchenne muscular dystrophy 
DYS = dystrophin 
EB = embryoid bodies 
ECM = extracellular matrix 
ES = embryonic stem 
FACS = fluorescence activated cell sorting 
Flk-1 = fetal liver kinase 1 
Foxk1 = forkhead box protein k1 
GFP = green fluorescent protein 
GSK-3 = glycogen synthase kinase 3  
DYS-HAC = human artificial chromosome containing the entire dystrophin locus 
HAC = human artificial chromosome 
HIDEMs = human iPS-derived mesoangioblast-like cells 
HLA = human leukocyte antigen 
HR = homologous recombination 
iPS = induced pluripotent stem 
IV = systemic intravenous delivery 
Klf4 = kruppel-like factor 4  
LGMD2D = limb-girdle muscular dystrophy 2D 
µUTRN = micro-utrophin 
MDSC = muscle-derived stem cells  
mdx = X chromosome-linked muscular dystrophy 
MHC = major histocompatibility complex 
MM = Miyoshi myopathy  
Myf5 = myogenic factor 5 
Myf6 = myogenic factor 6 
MyHC = myosin heavy chain  
MyoD = myogenic differentiation 1 
NCAM = neural cell adhesion molecule (otherwise known as CD56) 
NK = natural killer 
NSCs = neural stem cells 
Oct-4 = octamer-binding transcription factor 4  
Pax3 = paired box 3 
Pax7 = paired box 7 
PDGF-αR = platelet-derived growth factor-α receptor 
SCID = severe combined immunodeficient  
Sgca = α-sarcoglycan 
Sox2 = sex determining region Y-box 2  
TALENs = transcription activator-like effector nucleases  
VCAM-1 = vascular cell adhesion molecule 1 
ZFNs = zinc finger nucleases 
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Pluripot
ent stem 
cell 
Origin Myogenic differentiation method  
Mouse model & genetic 
correction 
In vivo results 
Refere
nce Engraftment/ Differentiation 
Systemic 
delivery 
Functional 
test 
ES cells 
mouse 
EB cocultured with primary 
muscle cells 
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✗ ✗ [85] 
MyoD integration (IND)  
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✗ ✗ [90] 
Pax3 integration (IND), EB, 
PDGF- αR+ Flk-1- cell 
sorting 
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✔  ✔  [91] 
Pax3 or Pax7 integration 
(IND), EB, PDGF- αR+ Flk-
1- cell sorting 
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✔  ✔  [92] 
mesodermal commitment, 
PDGF- αR+ cell sorting 
WT cells into 
immunodeficient mouse, 
no genetic correction 
✔  ✗ ✗ [95] 
EB and SM/C-2.6 cell sorting  
WT cells into mdx 
mouse, no genetic 
correction 
✔ ✗ ✗ [96] 
EB, GSK-3 inhibitor 
(CHIR99021), bFGF, N2 NA ✗ ✗ ✗ [98] 
Myf5 integration (IND), EB NA ✗ ✗ ✗ [94] 
human 
mesenchymal commitment, 
CD73+ and NCAM+ cell 
sorting 
HD cells into 
immunodeficient mouse, 
no genetic correction 
✔  ✗ ✗ [86] 
Pax7 LV integration (IND), 
EB, purification by cell 
sorting 
HD cells into 
immunodeficient/mdx 
mouse, no genetic 
correction 
✔  ✗ ✔  [93] 
EB, mesenchymal 
commitment 
HD cells into 
immunodeficient mouse, 
no genetic correction 
✔  ✗ ✗ [138] 
myogenic medium, MyoD 
AAV 
HD cells into 
immunodeficient/mdx 
mouse, no genetic 
correction 
✔  ✗ ✗ [133] 
BAF60C and MyoD LV 
integration NA ✗ ✗ ✗ [99] 
  GSK-3 inhibitor (CHIR99021), bFGF, N2 NA ✗ ✗ ✗ [98] 
  Myf5 integration (IND), EB NA ✗ ✗ ✗ [94] 
  
mesodermal commitment, 
MyoD-ER LV integration 
(IND) 
NA ✗ ✗ ✗ [131] 	  
Table 1. Summary of muscle differentiation and genetic correction in ES cells. 
AAV = Adeno associated viral vector, BAF60C also called SMARCD3 = SWI/SNF-related matrix-associated actin-dependent regulator 
of chromatin subfamily D member 3, bFGF = Basic fibroblast growth factor, DMD = Duchenne muscular dystrophy, EB = Embryoid 
bodies, Flk-1 = fetal liver kinase 1, GSK-3 inhibitor = Glycogen synthase kinase-3 inhibitor, HAC = Human artificial chromosome, HD 
= Healthy donor, IND = Inducible differentiation, LV = Lentiviral vector, mdx = X chromosome-linked muscular dystrophy, Myf5 = 
myogenic factor 5, NA = Not assessed (no disease, no genetic correction, in vitro only), MyoD = myogenic differentiation 1, NCAM = 
neural cell adhesion molecule, N2 = N2 supplemented media, Pax3 = paired box 3, Pax7 = paired box 7, PDGF-αR = platelet-derived 
growth factor-α receptor, WT = Wild type. 	  	  	  	  	  	  	  	  	  	  	  
Plurip
otent 
stem 
cell 
Origin Myogenic differentiation method  
Mouse model & genetic 
correction 
In vivo results 
Refere
nce Engraftment/ Differentiation 
Systemic 
delivery 
Functional 
test 
iPS 
cells 
Mouse 
Pax7 integration (IND), 
EB, PDGF-αR+ Flk-1- 
cell sorting 
WT cells into mdx mouse, no 
genetic correction ✔ ✗ ✔  [128] 
Pax3 LV integration 
(IND), EB, PDGF-αR+ 
Flk-1- cell sorting 
µutrn-SB transposon corrected, 
dys null/µutrn positive cells into 
dys null/utrn null mouse 
✔  ✔  ✔  [130] 
mesodermal 
commitment, MyoD-ER 
LV integration (IND) 
WT cells into Sgca-
null/immunodeficient mouse, 
no genetic correction 
✔  ✔  ✔  [9, 132] 
EB and SM/C-2.6 cell 
sorting  
WT cells into mdx mouse, no 
genetic correction ✔  ✗ ✗ [137] 
Pax3 transposon 
integration and EB NA ✗ ✗ ✗ [129] 
Human 
Pax7 LV integration 
(IND), EB, purification 
by cell sorting 
HD cells into immunodeficient 
or immunodeficient/mdx 
mouse, no genetic correction 
✔  ✗ ✔  [93] 
EB, mesenchymal 
commitment 
HD cells into immunodeficient 
mouse, no genetic correction ✔  ✗ ✗ [138] 
treatment with GSK-3 
inhibitor (CHIR99021) 
and bFGF, sorting for 
AChR+ or CXCR4+/C-
MET+ 
NA ✗ ✗ ✗ [139] 
EB and treatment with 
GSK-3 inhibitor (BIO), 
bFGF and forskolin 
HD cells into immunodeficient 
mouse, no genetic correction ✔  ✗ ✗ [140] 
mesodermal 
commitment, MyoD-ER 
LV integration (IND) 
LGMD2D: HD and LGMD2D 
cells, Sgca-LV corrected cells 
into Sgca-null/immunodeficient 
mouse 
✔  ✔  ✗ [9,131,132] 
DMD: DMD cells and DYS-
HAC corrected, in vitro only ✗ ✗ ✗ 
[9, 
131] 
myogenic medium, 
MyoD AAV 
DMD: DMD cells into 
immunodeficient/mdx mouse, 
no genetic correction 
✔  ✗ ✗ [133] 
MyoD (IND) PB-
transposon integration 
HD cells into 
immunodeficient/Dmd mouse, 
no genetic correction 
✔  ✗ ✗ [134] 
MM: DYSF-PB transposon 
corrected, in vitro only ✗ ✗ ✗ [134] 
CPT II: no genetic correction, 
in vitro only ✗ ✗ ✗ [135] 
MyoD LV integration 
(IND) 
HD, DMD, Becker, no genetic 
correction, in vitro only ✗ ✗ ✗ [136] 	  
Table 2. Summary of muscle differentiation and genetic correction in iPS cells.	  
AChR = acetylcholine receptor, AAV = Adeno associated viral vector, bFGF = Basic fibroblast growth factor, Becker = Becker muscular 
dystrophy, BIO = GSK-3β inhibitor, CPT II = Carnitine palmitoyltransferase II, C-MET = hepatocyte growth factor c MET receptor, 
CXCR4 = C-X-C chemokine receptor type 4, DYS-HAC = human artificial chromosome containing the entire dystrophin locus, DMD = 
Duchenne muscular dystrophy, dys = Dystrophin, DYSF = dysferlin, EB = Embryoid bodies, Flk-1 = fetal liver kinase 1, GSK-3 = 
Glycogen synthase kinase-3 inhibitor, HAC = Human artificial chromosome, HD = Healthy donor, IND = Inducible differentiation, 
LGMD2D = Limb girdle muscular dystrophy type 2D, LV = Lentiviral vector,  µUTRN = micro-utrophin, mdx = X chromosome-linked 
muscular dystrophy, MM = Myoshi myopathy, MyoD = myogenic differentiation 1, ER= Estradiol receptor, NA = Not assessed (no 
disease, no genetic correction, in vitro only), N2 = N2 supplemented media, Pax3 = paired box 3, Pax7 = paired box 7, PB = piggyBac, 
PDGF-αR = platelet-derived growth factor-α receptor, SB = Sleeping Beauty, Sgca =  α-sarcoglycan, utrn = Utrophin, WT = Wild Type.  	  	  	  	  	  
	  
